Keywords
peer review
This article is included in the Research on Research, Policy & Culture gateway.
This article is included in the All trials matter collection.
peer review
Stephen Senn challenges Ben Goldacre’s assertion in ‘Bad Pharma’1 that biased editorial acceptance of reports with ‘positive’ findings is not a cause of biased under-reporting of research, and concludes that "the prospects for disentangling cause and effect when it comes to publication bias are not great"2. Senn apparently overlooks the studies – including controlled experiments - which have investigated reporting biases. These are summarised in an article3 from which the following is an excerpt:
“Who is responsible for biased reporting of clinical research?
Reporting bias can be due to researchers and sponsors failing to submit study findings for publication, or due to journal editors and others rejecting reports for publication. Numerous surveys of investigators have left little doubt that almost all failure to publish is due to the failure of investigators to submit reports for publication4,5, with only a small proportion of studies remaining unpublished because of rejection by journals6, although positive-outcome bias has been demonstrated among peer reviewers7. Qualitative studies of editorial discussion indicate that a study’s scientific rigour is the area of greatest concern8. Researchers report that the reason they do not write up and submit reports of their research for publication is usually because they are "not interested" in the results ("editorial rejection by journals" is only rarely given as a cause of failure to publish). Even those investigators who have initially published their results as (conference) abstracts are less likely to submit their findings for full publication unless the results are ‘significant’9.
Investigations of biased reporting of research began with surveys of journal articles, which revealed improbably high proportions of published studies showing statistically significant differences10–14. Subsequent surveys of authors and peer reviewers showed that research that had yielded ‘negative’ results was less likely than other research to be submitted or recommended for publication15–18. These findings have been reinforced by the results of experimental studies, which showed that studies with no reported statistically significant differences were less likely to be accepted for publication7,19–21".
Senn’s use of the term ‘publication bias’ in his commentary suggests that he is restricting it to editorial bias whereas, as indicated above, the origins of reporting bias are largely due to researchers’ decisions not to submit, not editorial decisions not to accept. The analyses of observational data cited by Ben Goldacre in his book ‘Bad Pharma’1 do not detect editorial bias, but neither do they support a confident conclusion that no editorial bias exists. However, we believe Goldacre is correct to castigate researchers and research sponsors as being more culpable than editors in betraying their responsibility to the patients who have participated in trials.
The controlled experiments suggest that it is the results of studies, not their quality, that predisposes them to editorial bias. Senn believes that any editorial bias that exists can be ‘very plausibly explained’ by preferential publication of ‘positive’ studies, and that it "seems plausible that higher quality studies are more likely to lead to a positive result". Unless he is using the word ‘positive’ to mean something other than ‘a beneficial effect’, however, Senn appears to be overlooking substantial evidence challenging the plausibility of his belief (see, for example, reference22). Given the estimated likelihood of new treatments proving superior to standard treatments23 it surprises us that, "as a statistician" Senn would find this evidence "unpalatable".
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Competing Interests: No competing interests were disclosed.
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | |||
---|---|---|---|
1 | 2 | 3 | |
Version 1 02 Jan 13 |
read | read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)